STOCK TITAN

GE HealthCare to feature Mobile Mammography Screening Truck along with Latest AI Platform as part of SBI2024 Breast Cancer Imaging Showcase

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
AI
Rhea-AI Summary
GE HealthCare to Showcase Latest Breast Cancer Detection Technology at SBI 2024 Symposium
Positive
  • None.
Negative
  • None.

The integration of artificial intelligence (AI) in mammography, as demonstrated by GE HealthCare's MyBreastAI Suite, represents a significant advancement in breast cancer detection. This technology notably addresses the limitations of traditional mammograms in women with dense breast tissue. By incorporating AI applications such as ProFound AI for DBT, SecondLook for 2D Mammography and PowerLook Density Assessment, clinicians can potentially identify malignancies earlier, which is critical given that early detection is a key factor in improving survival rates.

From a research perspective, the operational productivity improvements promised by the MyBreastAI Suite could reduce the time radiologists spend on each case, allowing for a higher volume of screenings without sacrificing accuracy. This efficiency gain could translate into increased capacity for healthcare providers and potentially lead to reduced wait times for patients.

GE HealthCare's showcase of the Pristina Bright solution at the Society of Breast Imaging Symposium could have implications for the adoption of Contrast-Enhanced Mammography (CEM) technology. The comprehensive solution aims to simplify the process for healthcare providers to start new contrast programs, which could lead to wider utilization of CEM. Given that CEM has been shown to reveal lesions not visible in routine mammography, its increased adoption could lead to better diagnostic outcomes for patients.

The business impact of such technology extends to the potential for healthcare facilities to market their advanced capabilities to referring doctors and patients. Facilities that adopt the Pristina Bright offering may gain a competitive edge by differentiating their services with the ability to perform rapid biopsies and handle a higher throughput of patients, which could ultimately affect their financial performance and market share within the diagnostic imaging sector.

  • The latest MyBreastAI Suite* supports clinicians in accelerating breast cancer detection, while the company’s Pristina Bright** solution helps healthcare providers start a new contrast program.

MONTREAL--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC), a leader in breast health technology and diagnostics, will feature its latest breast cancer detection technology during the 2024 Society of Breast Imaging Symposium in Montreal, Canada, April 11-14, 2024. This year’s showcase will feature the Mobile Mammography Screening Truck, the recently released MyBreastAI Suite* and Pristina Bright** offering to demonstrate the company’s personalized approach to transforming breast cancer imaging.

Breast cancer is the most commonly diagnosed cancer among women, with one in eight facing diagnosis in their lifetime.1 Regular mammograms are critical, but their effectiveness is reduced in women with dense breast tissue, who are four to six times more likely to develop breast cancer.2 As a result, clinicians are turning to supplemental screening options and artificial intelligence (AI) technologies to help enhance the detection and diagnosis of breast cancer, improve patient outcomes, and help with radiology workflow so more patients can benefit from the world’s most sophisticated mammography tools.3

GE HealthCare’s latest MyBreastAI Suite provides an all-in-one AI platform optimized for mammography to support clinicians with breast cancer detection. With this initial release, MyBreastAI Suite integrates three AI applications from iCAD including ProFound AI for DBT, SecondLook for 2D Mammography and PowerLook Density Assessment to help support early detection and improve patient outcomes, as well as help radiology departments improve operational productivity.

"As part of GE HealthCare’s ongoing commitment to transform healthcare and improve patient outcomes, we continue to explore how we can leverage the power of AI in mammography to support the early detection of breast cancer,” says Pooja Pathak – Vice President and General Manager of Mammography. “We look forward to sharing this latest tool in our portfolio of technologies for personalized breast cancer care with the breast imaging community this year at SBI2024.”

Contrast-Enhanced Mammography (CEM), a technology first pioneered by GE HealthCare in 2010, is a game changer in breast diagnostic imaging and biopsy care - with over 200 publications that demonstrate its clinical performances.

In an effort to help further advance breast cancer and support healthcare providers in starting a new contrast program, the company will also be showcasing its Pristina Bright offering - a comprehensive solution that combines SenoBright HD, Pristina Serena, and Serena Bright with an education program that includes dedicated on-site support, CME accredited self-assessment, and access to a users’ club to share with experts around the globe and leverage resources needed to market their facility among referring doctors and patients.

With Pristina Bright, clinicians can see lesions that cannot be seen on routine mammography4 5 6 and biopsy what is seen within 15 minutes.7 To help improve overall productivity, Pristina Bright can also help providers take more patients on their system, with the ability to image up to 30 patients a day with contrast mammography8 through an easy-to-read exam.

“Through our research and clinical experiences, contrast enhanced mammography (CEM) continues to emerge as game-changer in helping to improve breast cancer outcomes for patients facing this difficult diagnosis,” shares Dr. Jordana Phillips – Radiologist at Boston Medical Center. “When it comes to findings that are difficult to define, CEM leverages the addition of a contrast agent to highlight unusual areas of blood flow - providing an efficient yet familiar, patient-centric approach to evaluate the presence of cancer with high sensitivity and specificity. With contrast, we’re able to turn a normal mammogram into something that provides so much more information which accelerates our ability to make a confident diagnosis. We’re excited to be joining GE HealthCare and the breast imaging community at SBI 2024 to share more about our experience through the hands-on learning course, as well as share how we’ve implemented CEM as part of our efforts to provide personalized breast cancer care to community we serve.”

As part of the company’s commitment to enabling access to healthcare, GE HealthCare will have its mobile mammography showcase onsite. Attendees will have the unique opportunity to explore the capabilities of this unit designed to offer convenient screening set-up within the familiar environment of a workplace. The truck is equipped with the Senographe Pristina and Invenia ABUS to ensure accurate and efficient screenings.

Visit booth 301 to learn more about GE HealthCare’s personalized breast cancer screening solutions, including:

  • Senographe Pristina, a mammography system designed to provide a better patient experience and optimized for rapid diagnosis;
  • Invenia ABUS, the first FDA-approved automatic breast ultrasound supplemental screening specifically designed for detecting cancer in dense breast;
  • SenoBright HD Contrast Enhanced Mammography (CEM), which combines mammography and vascular-based screening methods to highlight areas of unusual blood-flow patterns that may indicate malignancy - helping reduce the masking effect of fibro glandular breast tissue so lesions can be more clearly identifiable; and
  • Serena Bright, the industry’s first contrast-guided biopsy solution which transforms the screening room into an interventional suite if medical indications recommend pathology.

*MyBreastAI suite is a commercial offering that includes GE HealthCare’s Edison Health Services platform, ProFound AI® for DBT, SecondLook for 2D Mammography and PowerLook® Density Assessment. These applications are provided by iCAD. MyBreastAI Suite is compatible with the latest versions of iCAD, Inc. as of November 14, 2023.

 

** Pristina Bright is a commercial offering including SenoBright HD, Pristina Serena and Serena Bright.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Follow us on LinkedIn, X (formerly Twitter), and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.

____________________

1 Breastcancer.org. Breast Cancer Facts and Statistics. Available at: https://www.breastcancer.org/facts-statistics. Last accessed March 2023.

2 Boyd NF et al. NEJM 2007; 356: 227-36.

3 Bashar, MD Abu; Begam, Nazia1. Breast cancer surpasses lung cancer as the most commonly diagnosed cancer worldwide. Indian Journal of Cancer 59(3):p 438-439, Jul–Sep 2022. | DOI: 10.4103/ijc.IJC_83_21.

4 Compared to without contrast.

5 Sung JS, et al. Performance of Dual-Energy Contrast-enhanced Digital Mammography for Screening Women at Increased Risk of Breast Cancer. Radiology. 2019 Oct;293(1):81-88.

6 Sorin V, et al. Contrast-Enhanced Spectral Mammography in Women With Intermediate Breast Cancer Risk and Dense Breasts. AJR Am J Roentgenol. 2018 Nov;211(5):W267-W274.

7 Data on file. GE HealthCare 2020.

8 Over 8 hours. Data on file, GE HealthCare 2019.

 

Emily Niles

Global Communications Leader – Women’s Health & X-ray

M 262.290.8089

emily.niles@gehealthcare.com

Source: GE HealthCare

FAQ

What will GE HealthCare feature at the 2024 Society of Breast Imaging Symposium?

GE HealthCare will feature its latest breast cancer detection technology, including the Mobile Mammography Screening Truck, MyBreastAI Suite, and Pristina Bright offering.

Why are supplemental screening options and AI technologies important in breast cancer detection?

Supplemental screening options and AI technologies help enhance the detection and diagnosis of breast cancer, improve patient outcomes, and support radiology workflow for more effective mammography tools.

What is included in GE HealthCare's MyBreastAI Suite?

MyBreastAI Suite integrates three AI applications from iCAD - ProFound AI for DBT, SecondLook for 2D Mammography, and PowerLook Density Assessment to aid in early detection and improve patient outcomes.

What is Contrast-Enhanced Mammography (CEM) and why is it significant?

CEM is a technology pioneered by GE HealthCare that enhances breast diagnostic imaging and biopsy care. It highlights areas of blood flow to provide more information for cancer detection with high sensitivity and specificity.

How can Pristina Bright help healthcare providers?

Pristina Bright can help providers see lesions not visible on routine mammography, perform biopsies within 15 minutes, and image up to 30 patients a day with contrast mammography for improved productivity.

GE HealthCare Technologies Inc.

NASDAQ:GEHC

GEHC Rankings

GEHC Latest News

GEHC Stock Data

36.80B
424.19M
6.76%
72%
2.67%
Irradiation Apparatus Manufacturing
Manufacturing
Link
United States of America
CHICAGO

About GEHC

ge healthcare (nyse: ge) provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. while we encourage and welcome comments to our linkedin page, these posts from members of the public do not necessarily represent ge healthcare views, and we do not confirm their accuracy or endorse them. ge healthcare is part of highly regulated medical device and pharmaceutical industry. posts and conversations may be removed as a result, but may be forwarded to other people within ge healthcare for follow-up as appropriate. as part of our commitment to you and to the rest of the linkedin members, we will do our best to ensure that the content on the page remains positive. however, since we cannot monitor every post or conversation feed, we realize that the occasional objectionable posts will pop up just from time to time. therefore, the company reserves the right to remove any postings at i